Our interest on CCL4 derives from its ability to attract NKTs among other immune cells, suggesting that in models of synucleinopathy the increased trafficking of some lymphocytic populations to the CNS might be in part mediated by CCL4 and that anti-CD1d immunotherapy might disrupt this process (Fig. 10). Here, CD1D is linked to synucleinopathy.